TOI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oncology Institute Inc (TOI) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows weak technical signals, negative price momentum, and lacks significant positive catalysts. While revenue growth is notable, the company's financials remain weak with negative net income and declining EPS. Additionally, hedge funds are selling heavily, and there is no indication of insider or congressional buying. For now, it is better to hold off on investing in TOI.
The stock's MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 46.342, and moving averages are converging, which does not signal a clear trend. The stock is trading near its pivot level of 2.763, with support at 2.525 and resistance at 3.002. Overall, the technical indicators suggest a lack of strong upward momentum.
Revenue growth of 36.70% YoY in Q3 2025 is a positive sign for the company's top-line performance.
Hedge funds are selling heavily, with a 47487.34% increase in selling activity over the last quarter. The company has a negative net income of -$13.77M and declining EPS (-22.22% YoY). No recent news, insider buying, or congressional trading data to indicate confidence in the stock.
In Q3 2025, revenue increased by 36.70% YoY to $136.56M, but net income remains negative at -$13.77M, albeit improving by 4.14% YoY. EPS dropped by 22.22% YoY to -0.14, and gross margin declined slightly to 12.59%. Overall, the company is growing revenue but struggling with profitability.
No recent analyst rating or price target changes available for TOI.
